%PDF-1.4
%
34 0 obj
<>
endobj
31 0 obj
<>
endobj
396 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-09-13T12:59:40Z
2024-03-28T17:43:29-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T17:43:29-07:00
application/pdf
Heather
2004-625.oct
uuid:11ad247e-1dd2-11b2-0a00-e80927edca00
uuid:11ad2480-1dd2-11b2-0a00-380000000000
endstream
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 10 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
408 0 obj
[413 0 R]
endobj
409 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6234 0.7818 -0.7818 0.6234 10.4844 52.3976 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 792 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 73.868 741.5293 Tm
(recombinant tumor necrosis factor receptor:Fc fusion protein, in)Tj
0 -1.25 TD
(patients with rheumatoid arthritis receiving methotrexate. N Engl J)Tj
0 Tc T*
(Med 1999;340:253-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875 (Louis M, Rauch J, )55 (Armstrong M, Fitzcharles M. Induction of)]TJ
2.175 -1.25 Td
(autoantibodies during prolonged treatment with infliximab. )Tj
T*
(J Rheumatol 2003;30:2557-62.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Shakoor N, Michalska M, Harris C, Block J. Drug-induced)]TJ
2.1381 -1.25 Td
[(systemic lupus erythematosus associated with etanercept therapy)65 (.)]TJ
T*
(Lancet 2002;359:579-80.)Tj
-2.175 -1.25 Td
[(12.)-875 (Charles P)111 (, Smeenk R, De Jong J, Feldmann M, Maini R.)]TJ
2.175 -1.25 Td
[(Assessment of antibodies to double-stranded DNA)-220 (induced in)]TJ
T*
(rheumatoid arthritis patients following treatment with infliximab, a)Tj
T*
(monoclonal antibody to tumor necrosis factor alpha. Findings in)Tj
T*
[(open-label and randomized placebo-controlled trials. )55 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:2383-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875 (Robinson )18 (W)92 (, Genovese M, Moreland L. Demyelinating and)]TJ
2.175 -1.25 Td
(neurologic events reported in association with tumor necrosis factor)Tj
T*
[(and antagonism. )55 (Arthritis Rheum 2001;44:1977-83.)]TJ
30.825 21.25 Td
[(14.)-875 (Mohan N, Edwards ET)74 (, Cupps )18 (TR, et al. Leukocytoclastic)]TJ
2.175 -1.25 Td
[(vasculitis associated with tumor necrosis factor)20 (-alpha blocking)]TJ
T*
(agents. J Rheumatol 2004;31:1955-8.)Tj
-2.175 -1.25 Td
[(15.)-875 (Galaria N, )18 (W)80 (erth )18 (V)129 (, Schumacher H. Leukocytoclastic vasculitis due)]TJ
2.175 -1.25 Td
(to etanercept. J Rheumatol 2000;27:2041-4.)Tj
-2.175 -1.25 Td
[(16.)-875 (Jarrett S, Cunnane G, Conaghan P)111 (, et al. )55 (Anti-tumor necrosis factor)20 (-)]TJ
2.175 -1.25 Td
(alpha therapy-induced vasculitis: case series. J Rheumatol)Tj
0 Tc 0 Tw T*
(2003;30:2287-91.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Mohan )55 (A, Edwards E, Cote )18 (T)74 (, Siegel J, Braun M. Drug-induced)]TJ
2.175 -1.25 Td
[(systemic lupus erythematosus and )18 (TNF-alpha blockers [comment].)]TJ
T*
(Lancet 2002;360:646.)Tj
-2.175 -1.25 Td
[(18.)-875 (De Miguel S, Jover J, )18 (V)111 (adillo C, Judez E, Loza E, Fernandez-)]TJ
2.175 -1.25 Td
(Gutierrez B. B cell activation in rheumatoid arthritis patients under)Tj
T*
(infliximab treatment. Clin Exp Rheumatol 2003;21:726-32.)Tj
ET
0 0 0 1 K
53.468 81 m
558.468 81 l
S
0 0 0 0 k
494.29 73.865 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 541.468 60.9344 Tm
(1887)Tj
ET
0 0 0 0 k
53.532 75 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 62.0695 Tm
(Guillevin and Mouthon: Editorial)Tj
ET
0 0 0 0 k
/GS0 gs
102.585 87.083 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.585 87.083 407.5 -10.833 re
S
Q
Q
q
1 0 0 1 8 10 cm
0 0 612 792 re
W n
1 0 0 1 -8 -10 cm
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
118.368 79 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
14 0 obj
<>stream
8;Z\t#nDSA$j?>)+7sb,l5OCZ/Nm)##S:CaEAihGa=dMooEFac\)IJhU3QN0lNeoKAB^'4(U/<+P^NB/_fNMZtj63.VNXh
9?C@o'\2MhR1?1)opsh7^POVJeMSM'&4-XGKFgHUq0VTTf0nCi9Ol1b9s
endstream
endobj
18 0 obj
[/Indexed/DeviceRGB 255 17 0 R]
endobj
17 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
98 0 obj
<>
endobj
51 0 obj
<>
endobj
38 0 obj
<>
endobj
91 0 obj
<>
endobj
402 0 obj
<>
endobj
37 0 obj
<>
endobj
70 0 obj
<>stream
HUiPSY~/<#c"˔U ,6 "K%l&bdEAnvEPizŪvj>/}陉v3uuNT qfv+ |qdػvcqfq"?8̈́EV&-ڂ~Q![ O,ڭ0ǩ>^;IAL_x7x]
m(>/P"D=DŽ)IH1?ڝ{R"~J1~b@ċS" )qHfsyYa?-ԥtmm:05Ux#tG:4>|2d\뗜hKThtS0L`Jo~QWۋ,C"ReT2ZFqv